Suppr超能文献

倍他司汀与奥昔布宁联合使用可提高阻塞性睡眠呼吸暂停患者的呼吸控制敏感性(环路增益):一项随机、安慰剂对照试验。

The Combination of Betahistine and Oxybutynin Increases Respiratory Control Sensitivity (Loop Gain) in People with Obstructive Sleep Apnea: A Randomized, Placebo-Controlled Trial.

作者信息

Messineo Ludovico, Loffler Kelly, Chiang Alan, Osman Amal, Taranto-Montemurro Luigi, Eckert Danny J

机构信息

Adelaide Institute for Sleep Health, Flinders University, Adelaide, SA, Australia.

Division of Sleep and Circadian Disorders, Departments of Medicine and Neurology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

出版信息

Nat Sci Sleep. 2022 Jun 7;14:1063-1074. doi: 10.2147/NSS.S362205. eCollection 2022.

Abstract

RATIONALE

There are widespread histaminergic projections throughout the brain, including hypoglossal nuclei, that modulate pharyngeal muscle tone and respiratory control. Hence, histaminergic stimulation pharmacologically may increase pharyngeal muscle tone and stabilize respiratory control (loop gain) to reduce obstructive sleep apnea (OSA) severity. Antimuscarinics also increase REM pharyngeal muscle tone in rats. Thus, a combination of histaminergic and anti-muscarinic drugs may be a novel target for OSA pharmacotherapy. However, this has not been investigated. Accordingly, we aimed to test the effects of betahistine (Beta), an H3-autoreceptor antagonist which thereby increases histamine levels, in combination with the antimuscarinic oxybutynin (Oxy), on OSA severity, OSA endotypes, polysomnography parameters and next-day sleepiness and alertness.

METHODS

Thirteen adults with OSA received either Beta-Oxy (96-5mg) or placebo according to a randomized, crossover, double-blind design, prior to polysomnography. Participants completed the Karolinska Sleep Scale and Leeds Sleep Evaluation Questionnaire and a driving simulation task to quantify next-day sleepiness and alertness. OSA endotypes were estimated through validated algorithms using polysomnography.

RESULTS

Compared to placebo, Beta-Oxy increased respiratory control sensitivity (loop gain) (0.52[0.24] vs 0.60[0.34], median [IQR], P = 0.021) without systematically changing OSA severity (34.4±17.2 vs 40.3±27.3 events/h, mean±SD, P = 0.124), sleep efficiency, arousal index or markers of hypoxemia. Beta-Oxy was well tolerated and did not worsen next-day sleepiness/alertness.

CONCLUSION

Rather than stabilize breathing during sleep, Beta-Oxy increases loop gain, which is likely to be deleterious for most people with OSA. However, in certain conditions characterized by blunted respiratory control (eg, obesity hypoventilation syndrome), interventions to increase loop gain may be beneficial.

摘要

原理

组胺能投射广泛分布于整个大脑,包括舌下神经核,可调节咽部肌肉张力和呼吸控制。因此,药理学上的组胺能刺激可能会增加咽部肌肉张力并稳定呼吸控制(环路增益),以降低阻塞性睡眠呼吸暂停(OSA)的严重程度。抗胆碱能药物也可增加大鼠快速眼动期咽部肌肉张力。因此,组胺能药物和抗胆碱能药物联合使用可能是OSA药物治疗的一个新靶点。然而,尚未对此进行研究。因此,我们旨在测试倍他司汀(Beta)(一种H3自受体拮抗剂,可提高组胺水平)与抗胆碱能药物奥昔布宁(Oxy)联合使用对OSA严重程度、OSA内型、多导睡眠图参数以及次日嗜睡和警觉性的影响。

方法

13名成年OSA患者根据随机、交叉、双盲设计,在进行多导睡眠图检查前接受倍他司汀 - 奥昔布宁(96 - 5mg)或安慰剂治疗。参与者完成卡罗林斯卡睡眠量表、利兹睡眠评估问卷以及一项驾驶模拟任务,以量化次日的嗜睡和警觉性。通过使用多导睡眠图的验证算法来估计OSA内型。

结果

与安慰剂相比,倍他司汀 - 奥昔布宁增加了呼吸控制敏感性(环路增益)(中位数[四分位间距]为0.52[0.24]对0.60[0.34],P = 0.021),但未系统性改变OSA严重程度(平均±标准差为34.4±17.2对40.3±27.3次/小时,P = 0.124)、睡眠效率、觉醒指数或低氧血症标志物。倍他司汀 - 奥昔布宁耐受性良好,且未使次日嗜睡/警觉性恶化。

结论

倍他司汀 - 奥昔布宁并非在睡眠期间稳定呼吸,而是增加环路增益,这对大多数OSA患者可能有害。然而,在某些以呼吸控制减弱为特征的情况下(如肥胖低通气综合征),增加环路增益的干预措施可能有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验